Therapeutic Solutions International Inc (TSOI)

[morgan8]

"We have received numerous enquiries about the newly Designated Series B 5% Preferred stock. Series B is for the purpose of funding phase 3 ARDs and will payout 5% of potential future revenues assuming a successful BLA with FDA. To provide any further detail you would first need to fill out an investors questionnaire for us to determine if you qualify as an accredited investor as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended."